Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 1.00 |
| ▸ | RARB | P10826 | 12/20 | 0.76 |
| ▸ | RARG | P13631 | 12/20 | 0.76 |
| ▸ | RARA | P10276 | 10/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | TP53 | P04637 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
| ▸ | HPGD | P15428 | 1/20 | 0.76 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.76 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.76 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29359220 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBRECQLNR2E1 | |
| SCHEMBL24795669 | 0.88 | MEN1 (0.78) | MEN1KMT2ATHRBRECQLNR2E1 | |
| SCHEMBL25870579 | 0.86 | MEN1 (0.76) | MEN1KMT2ATHRBRECQLNR2E1 | |
| SCHEMBL8657238 | 0.86 | MEN1 (0.76) | MEN1KMT2ATHRBRECQLNR2E1 | |
| O-Demethylated Adapalene SCHEMBL29357074 | 0.86 | RARG (1.00) | MEN1KMT2ATHRBRECQLNR2E1 | |
| O-Demethylated Adapalene SCHEMBL29357288 | 0.86 | RARG (1.00) | MEN1KMT2ATHRBRECQLNR2E1 | |
| O-Demethylated Adapalene SCHEMBL174205 | 0.86 | RARG (1.00) | MEN1KMT2ATHRBRECQLNR2E1 | |
| O-Demethylated Adapalene SCHEMBL29727107 | 0.86 | RARG (1.00) | MEN1KMT2ATHRBRECQLNR2E1 | |
| SCHEMBL7926577 | 0.86 | MEN1 (0.75) | MEN1KMT2ATHRBRECQLNR2E1 | |
| SCHEMBL12257861 | 0.85 | MEN1 (0.74) | MEN1KMT2ATHRBRECQLNR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 322 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| WO-2026086823-A1 | IN VITRO PRODUCTION OF EXPANDED POTENTIAL STEM CELLS | Centre for Translational Stem Cell Biology Limited (CN) | 2026-04-30 | — | — | WO | claimed |
| US-12605434-B2 | Composition for preventing or treating autoimmune diseases | STATENS SERUM INSTITUT (DK) | 2026-04-21 | — | — | US | claimed |
| US-20260053763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING RENAL CYSTIC CILIOPATHY | KYOTO UNIVERSITY (JP) | 2026-02-26 | — | — | US | claimed |
| WO-2025235403-A1 | DIFFERENTIATION OF PANCREATIC ISLET CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-11-13 | — | — | WO | claimed |
| US-20250333701-A1 | COMPOSITIONS AND METHODS FOR GENERATING HEMATOPOIETIC STEM CELLS (HSCS) | WASHINGTON UNIVERSITY ST LOUIS (US) | 2025-10-30 | — | — | US | claimed |
| EP-4574171-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING RENAL CYSTIC CILIOPATHY | Kyoto University (JP) | 2025-06-25 | — | — | EP | claimed |
| US-20250188422-A1 | INDUCED TOTIPOTENT POTENTIAL STEM CELLS, METHODS OF MAKING AND USING | PEKING UNIVERSITY (CN) | 2025-06-12 | — | — | US | claimed |
| CN-120091831-A | Pharmaceutical composition for treating and/or preventing cystic fibrosis of kidney | 国立大学法人京都大学 | 2025-06-03 | — | — | CN | claimed |
| US-20250170083-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING RENAL CYSTIC CILIOPATHY | KYOTO UNIVERSITY (JP) | 2025-05-29 | — | — | US | claimed |
| US-20190314339-A1 | Prophylactic and/or Therapeutic Drug for Diabetic Nephropathy | HUBIT GENOMIX, INC. (JP) | 2019-10-17 | — | — | US | claimed |
| US-20190134002-A1 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS | YAMAGUCHI UNIVERSITY (JP) | 2019-05-09 | — | — | US | claimed |
| US-9789074-B2 | Composition and method for muscle repair and regeneration | THOMAS JEFFERSON UNIVERSITY (US) | 2017-10-17 | — | — | US | claimed |
| US-9492431-B2 | Therapeutic agent for keratoconjunctive disorders | YAMAGUCHI UNIVERSITY (JP) | 2016-11-15 | — | — | US | claimed |
| US-20140363402-A1 | COMPOSITION AND METHOD FOR MUSCLE REPAIR AND REGENERATION | THOMAS JEFFERSON UNIVERSITY (US) | 2014-12-11 | — | — | US | claimed |
| EP-2613776-A2 | COMPOSITION AND METHOD FOR MUSCLE REPAIR AND REGENERATION | Thomas Jefferson University (US) | 2013-07-17 | — | — | EP | claimed |
| WO-2012030919-A2 | COMPOSITION AND METHOD FOR MUSCLE REPAIR AND REGENERATION | THOMAS JEFFERSON UNIVERSITY (US) | 2012-03-08 | — | — | WO | claimed |
| EP-0862910-B1 | Use of retinoids as skin pigmentation inducing agent | GALDERMA RECH DERMATOLOGIQUE (FR) | 2003-05-02 | — | — | EP | claimed |
| US-5124473-A | Skin disorders; antiinflammatory agents, antiallergens | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1992-06-23 | — | — | US | claimed |
| EP-0210929-B1 | AROMATIC POLYCYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL AND COSMETIC USE | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) | 1992-06-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314339-A1 | Prophylactic and/or Therapeutic Drug for Diabetic Nephropathy | BMP4, RARG, RARB | MEN1 4444/4885KMT2A 2317/4885THRB 1043/4885 |
| US-20260053763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING RENAL CYSTIC CILIOPATHY | PKD1, RARB, PKD2 | MEN1 4012/4885KMT2A 4781/4885THRB 210/4885 |
| US-12605434-B2 | Composition for preventing or treating autoimmune diseases | TMSB10, RXRB, MALT1 | MEN1 1350/4885KMT2A 2893/4885THRB 17/4885 |
| US-20190134002-A1 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS | RARG, RARB, RARA | MEN1 4882/4885KMT2A 3104/4885THRB 382/4885 |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | WNT3A, GSK3B, GSK3A | MEN1 4529/4885KMT2A 1758/4885THRB 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.